Claims for Patent: 9,603,898

Summary for Patent: 9,603,898

Title:	Formulations of diluted amino acid segments and methods for making same
Abstract:	A formulation of a diluted amino acid segment is prepared by mixing an amino acid segment and a diluting agent to form a mixture. The mixture is serially diluted to produce a diluted formulation. The amino acid segment includes a peptide sequence that is the same as a portion of a longer peptide sequence found in a naturally occurring material. A homeopathic remedy can be prepared using the formulation.
Inventor(s):	Carter; Jacob L. (Pleasant Grove, UT), Lephart; Edwin Douglas (Orem, UT)
Assignee:	Deseret Biologicals, Inc. (Sandy, UT)
Application Number:	13/428,907
Patent Claims:	1. A method comprising: mixing an amino acid segment and a diluting agent to form a mixture; and serially diluting at least a portion of the mixture to produce a diluted formulation having a concentration of the amino acid segment that is no more than 1.times.10.sup.-10 w/w; wherein the amino acid segment includes a peptide sequence of at least five amino acids that is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin; and wherein the amino acid segment is not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin. 2. The method of claim 1 wherein the peptide sequence includes at least ten amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 3. The method of claim 1 wherein the peptide sequence includes at least fifteen amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 4. The method of claim 1 wherein the peptide sequence includes at least twenty amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 5. The method of claim 1 wherein the peptide sequence is a first peptide sequence, the amino acid segment including a second peptide sequence of at least five amino acids that is the same as a terminal end of the alpha subunit of human chorionic gonadotropin. 6. The method of claim 5 wherein the second peptide sequence is the same as the N-terminal end of the alpha subunit of human chorionic gonadotropin. 7. The method of claim 5 wherein the second peptide sequence includes at least ten amino acids and is the same as the terminal end of the alpha subunit of human chorionic gonadotropin. 8. The method of claim 1 wherein at least 50% w/w of the amino acid segments in the mixture each include a peptide sequence of at least five amino acids that is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin, and wherein the at least 50% w/w of the amino acid segments are not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin. 9. The method of claim 1 wherein serially diluting at least a portion of the mixture includes producing successive, increasingly dilute mixtures and vigorously mixing each increasingly dilute mixture. 10. The method of claim 1 wherein serially diluting at least a portion of the mixture includes producing successive, increasingly dilute mixtures using the same dilution ratio for each increasingly dilute mixture. 11. The method of claim 1 wherein the mixture is serially diluted using an average dilution ratio of no more than approximately 1:5. 12. The method of claim 1 wherein the mixture is serially diluted at least three times. 13. The method of claim 1 wherein the potency of the diluted formulation is at least 20V, 10X, or 5C. 14. A method comprising: mixing an amino acid segment and a diluting agent to form a mixture; repeatedly diluting at least a portion of the mixture to produce successive, increasingly dilute mixtures including a dilute mixture having a concentration of the amino acid segment that is no more than 1.times.10.sup.-10 w/w; and succussing each increasingly dilute mixture; wherein the amino acid segment includes a peptide sequence of at least five amino acids that is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin; and wherein the amino acid segment is not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin. 15. The method of claim 14 wherein the peptide sequence includes at least ten amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 16. The method of claim 14 wherein the peptide sequence includes at least fifteen amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 17. The method of claim 14 wherein the peptide sequence includes at least twenty amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 18. The method of claim 14 wherein the peptide sequence is a first peptide sequence, the amino acid segment including a second peptide sequence of at least five amino acids that is the same as a terminal end of the alpha subunit of human chorionic gonadotropin. 19. The method of claim 14 wherein at least 50% w/w of the amino acid segments in the mixture each include a peptide sequence of at least five amino acids that is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin, and wherein the at least 50% w/w of the amino acid segments are not the same as the complete peptide sequence of either the alpha or beta subunit of human chorionic gonadotropin. 20. The method of claim 14 wherein the same dilution ratio is used to produce each increasingly dilute mixture. 21. The method of claim 14 wherein each increasingly dilute mixture is diluted using an average dilution ratio of no more than approximately 1:5. 22. The method of claim 14 wherein repeatedly diluting at least a portion of the first mixture produces at least three increasingly dilute mixtures. 23. A packaged formulation comprising: a container; a homeopathic formulation inside the container, the homeopathic formulation being produced by the method recited in claim 1; and a label attached to the container. 24. The packaged formulation of claim 23 wherein the peptide sequence includes at least ten amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 25. The packaged formulation of claim 23 wherein the peptide sequence includes at least fifteen amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 26. The packaged formulation of claim 23 wherein the peptide sequence includes at least twenty amino acids and is the same as the C-terminal end of the beta subunit of human chorionic gonadotropin. 27. The packaged formulation of claim 23 wherein the peptide sequence is a first peptide sequence, the amino acid segment including a second peptide sequence of at least five amino acids that is the same as a terminal end of the alpha subunit of human chorionic gonadotropin. 28. The packaged formulation of claim 27 wherein the second peptide sequence is the same as the N-terminal end of the alpha subunit of human chorionic gonadotropin. 29. The packaged formulation of claim 27 wherein the second peptide sequence includes at least ten amino acids and is the same as the terminal end of the alpha subunit of human chorionic gonadotropin. 30. The packaged formulation of claim 23 wherein the homeopathic formulation is liquid. 31. The packaged formulation of claim 23 wherein the homeopathic formulation is in the form of a pellet, tablet, or capsule.

Details for Patent 9,603,898

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974		2032-03-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984		2032-03-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985		2032-03-23
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990		2032-03-23
Bel-mar Laboratories, Inc.	CHORIONIC GONADOTROPIN	chorionic gonadotropin	Injection	017054	March 26, 1974		2032-03-23
Fresenius Kabi Usa, Llc	CHORIONIC GONADOTROPIN	chorionic gonadotropin	For Injection	017067	March 05, 1973		2032-03-23